Nitrofurantoin and congenital abnormalities

Andrew E. Czeizel, Magda Rockenbauer, Henrik T. Sorensen, Jorn Olsen

Research output: Contribution to journalArticle

28 Citations (Scopus)


Objective: To study human teratogenic potential of oral nitrofurantoin treatment during pregnancy. Materials and Methods: Pair analysis of cases with congenital abnormalities and matched population controls in the population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. Results: Of 38,151 pregnant women who had newborn infants without any congenital abnormalities (population control group), 774 (3.4%); of 22,865 case pregnant women who had newborns or fetuses with congenital abnormalities, 1079 (2.8%) and of 812 pregnant women who had newborns or fetuses with Down's syndrome (patient controls), 23 (2.8%) pregnant women were treated with nitrofurantoin. The above differences between population controls and cases may be connected with recall bias, because the case-control pair analysis did not indicate a teratogenic potential of nitrofurantoin use during the second and the third months of gestation, i.e. in the critical period for major congenital abnormalities. Conclusion: Treatment with nitrofurantoin during pregnancy does not present detectable teratogenic risk to the fetus.

Original languageEnglish
Pages (from-to)119-126
Number of pages8
JournalEuropean Journal of Obstetrics and Gynecology and Reproductive Biology
Issue number1
Publication statusPublished - Jan 1 2001



  • Case-control analysis
  • Congenital abnormalities
  • Human teratogenic potential
  • Nitrofurantoin

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynaecology

Cite this